Um estudo para testar se o tratamento com BI 770371 em combinação com pembrolizumab com ou sem cetuximab ajuda pessoas com câncer de cabeça e pescoço em comparação com pembrolizumab sozinho
Uma fase IB Label aberto Ensaio clínico randomizado para avaliar a segurança e a eficácia do BI 770371 em combinação com o pembrolizumab com ou sem cetuximabe em comparação com a monoterapia do pembrolizumab para o tratamento de primeira linha de pacientes com carcinoma de células escamosas metastáticas ou recorrentes e de coleta (HNSCC)
This study is open to adults with head and neck cancer. The purpose of this study is to find out whether combining different study medicines makes tumors shrink in people with head and neck cancer.
The tested medicines in this study are antibodies that act in different ways against cancer. BI 770371 and pembrolizumab may help the immune system fight cancer. Cetuximab blocks growth signals and may prevent the tumor from growing.
Participants are put into 3 groups randomly. Each group receives a different combination of study medicines. All study medicines are given as an infusion into a vein at the study site.
Participants can stay in the study as long as they benefit from treatment. Doctors regularly check the size of the tumor and check whether it has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects.
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Braunschweig, Alemanha, 38114
- Städtisches Klinikum Braunschweig gGmbH
-
Jena, Alemanha, 07743
- Universitätsklinikum Jena
-
Leipzig, Alemanha, 04103
- Universität Leipzig
-
Ulm, Alemanha, 89081
- Universitätsklinikum Ulm
-
-
-
-
New South Wales
-
Gosford, New South Wales, Austrália, 2250
- Gosford Hospital
-
-
Victoria
-
Geelong, Victoria, Austrália, 3220
- Andrew Love Cancer Centre
-
-
-
-
-
Barretos, Brasil, 14784-400
- Hospital de Amor
-
Natal, Brasil, 59062-000
- Liga Norte Riograndense contra o cancer
-
São José do Rio Preto, Brasil, 15090-000
- Fundaçao Faculdade Regional de Medicina de Sao Jose do Rio Preto
-
-
-
-
-
Sofia, Bulgária, 1404
- MBAL Sveta Sofia
-
-
-
-
-
Singapore, Cingapura, 119228
- National University Hospital-Singapore-22806
-
-
-
-
-
Seoul, Coréia do Sul, 03722
- Severance Hospital
-
Seoul, Coréia do Sul, 135-710
- Samsung Medical Center
-
Suwon, Coréia do Sul, 16247
- The Catholic University of Korea, St.Vincent's Hospital
-
-
-
-
-
Barcelona, Espanha, 08035
- Hospital Universitari Vall d'Hebron
-
-
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40202
- Norton Cancer Institute, Downtown
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- M Health Fairview Clinics and Surgery Center - Minneapolis
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- The Ohio State University Wexner Medical Center
-
-
-
-
-
Lille, França, 59020
- CTR Oscar Lambret
-
Lyon, França, 69373
- CTR Leon Berard
-
Marseille, França, 13385
- HOP Timone
-
Villejuif, França, 94805
- Institut Gustave Roussy
-
-
-
-
-
Tbilisi, Geórgia, 0112
- ARENSIA Exploratory Medicine LLC
-
-
-
-
-
Budapest, Hungria, 1083
- Semmelweis University
-
Gyöngyös, Hungria, 3200
- Clinexpert Gyongyos
-
-
-
-
-
Meldola (FC), Itália, 47014
- Istituto Scientifico Romagnolo
-
Verona, Itália, 37126
- Azienda Ospedaliera Universitaria Integrata Verona
-
-
-
-
-
Hokkaido, Sapporo, Japão, 060-8648
- Hokkaido University Hospital
-
Hyogo, Kobe, Japão, 650-0017
- Kobe University Hospital
-
Osaka, Hirakata, Japão, 573-1191
- Kansai Medical University Hospital
-
Shizuoka, Sunto-gun, Japão, 411-8777
- Shizuoka Cancer Center
-
Tokyo, Koto-ku, Japão, 135-8550
- Japanese Foundation for Cancer Research
-
-
-
-
-
Chisinau, Moldávia, MD-2025
- ARENSIA Exploratory Medicine
-
-
-
-
-
Mexico City, México, 04660
- Unidad Clinica Farmacologica Bioemagno
-
México, México, 14080
- Instituto Nacional de Cancerologia
-
México, México, 06760
- Centro Oncologico Personalizado
-
Tlajomulco de Zuñiga, México, 45640
- Centro Oncológico Internacional
-
-
-
-
-
Lublin, Polônia, 20090
- Center of Oncology of the Lublin Region St. Jana z Dukli
-
-
-
-
-
London, Reino Unido, EC1A 7BE
- St Bartholomew's Hospital
-
London, Reino Unido, SW3 6JJ
- The Royal Marsden Hospital, Chelsea
-
Sutton, Reino Unido, SM2 5PT
- The Royal Marsden Hospital, Sutton
-
-
-
-
-
Bucharest, Romênia, 022328
- "Prof. Dr. Alexandru Trestioreanu" Oncology Institut
-
-
-
-
-
Aarau, Suíça, 5001
- Cantonspital Aarau
-
-
-
-
-
Bangkoknoi, Tailândia, 10700
- Siriraj Hospital
-
-
-
-
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
Taipei, Taiwan, 10048
- National Taiwan University Hospital
-
-
-
-
-
Adana, Turquia (Türkiye), 01220
- Adana City Hospital
-
Ankara, Turquia (Türkiye), 06800
- Ankara Bilkent City Hospital
-
Ankara, Turquia (Türkiye), 06200
- Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
Ankara, Turquia (Türkiye), 06230
- Hacettepe University Oncology Hospital
-
Istanbul, Turquia (Türkiye), 34093
- Istanbul University Medical Faculty Capa Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patients with histologically confirmed metastatic or recurrent HNSCC of the primary tumour location of oral cavity, oropharynx, hypopharynx, and larynx not amenable to locoregional treatment with curative intent.
- Willingness to provide pretreatment (baseline) biopsy/tissue to the sponsor (fresh or archival one). A newly obtained biopsy is preferred but an archival sample is acceptable, with tumor tissue (formalin fixed paraffin embedded [FFPE] block preferred, or at least 10 freshly sectioned unstained FFPE slides) from a core or excisional biopsy. Any deviation from this rule requires approval by the sponsor. Details on the requirements for archival tumour tissue and on biopsy sample collection are provided in the Laboratory Manual.
- Patients who have not received prior systemic treatment for metastatic or recurrent HNSCC. Systemic therapy (including cetuximab) which was completed more than 6 months prior to progression of disease if given as part of multimodal treatment for locally advanced disease is allowed.
- Patients who do not have contraindications to pembrolizumab monotherapy according to pembrolizumab local label, guidelines, treatment standards, regulations or the document (label of another country if pembrolizumab local label is not available) provided in the investigator site file (ISF) by the sponsor.
- Patients who do not have contraindications to treatment with cetuximab according to cetuximab local label, guidelines, treatment standards, regulations, or the document (label of another country if cetuximab local label is not available) provided in the ISF by the sponsor.
- Presence of at least one measurable non-central nervous system (CNS) lesion (according to RECIST v1.1.).
- Further inclusion criteria apply.
Exclusion Criteria:
- Nasopharyngeal carcinoma (NPC) of any histology, primary tumour location at nasal cavity, paranasal sinuses of any histology, any cancer of unknown primary.
- Any tumour location necessitating an urgent therapeutic intervention (e.g., palliative care, surgery, or radiation therapy), such as spinal cord compression, other compressive mass, uncontrolled painful lesion, bone fracture.
- Patients with progressive HNSCC within 6 months of completion of systemic therapy for locoregionally advanced disease with curative intent.
- Receiving treatment for brain metastases or leptomeningeal disease (LMD) which may interfere with safety and/or endpoint assessment. Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to trial entry, have discontinued corticosteroid treatment for these metastases and are clinically stable, off anticonvulsants for at least 4 weeks and are neurologically stable before enrollment.
- Patients for whom single agent pembrolizumab is not the preferred treatment (e.g. patients for whom chemotherapy or anti-PD-1 in combination with chemotherapy is considered the preferred therapy by the investigator or treating physician).
- Prior treatment with any anti signal regulatory protein alpha (SIRPα) or anti-integrin-associated protein (CD47) agent, regardless of treatment intent.
- Prior cancer treatment with any anti PD-1 or anti PD-L1 agent or with an agent directed to another stimulatory or co-inhibitory Tcell receptor (e.g. CTLA-4, OX 40, CD137), regardless of treatment intent.
- Prior allogeneic stem cell or solid organ transplantation.
- Further exclusion criteria apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Pembrolizumabe
|
Pembrolizumab |
|
Experimental: Pembrolizumab + BI 770371
|
Pembrolizumab BI 770371 |
|
Experimental: Pembrolizumab + BI 770371 + cetuximab
|
Pembrolizumab BI 770371 Cetuximab |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Objective response (OR) with confirmation
Prazo: Up to 27 months
|
OR defined as the best overall response of complete response (CR) or partial response (PR), where best overall response is determined according to response evaluation criteria in solid tumours version 1.1 (RECIST v1.1). Objective response (OR) will be defined by investigator's assessment from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, lost to follow-up or withdrawal of consent. |
Up to 27 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Ocorrência do evento adverso relacionado ao tratamento (AE) da Primeira Administração de Tratamento até o primeiro de 90 dias após a última dose, morte, terapia subsequente anticâncer, perdeu para acompanhamento ou retirada do consentimento
Prazo: Até 27 meses
|
Até 27 meses
|
|
|
Ocorrência de EA relacionada ao tratamento, levando à descontinuação do tratamento da Primeira Administração de Tratamento até os mais cedo de 90 dias após a última dose, morte, terapia subsequente anticâncer, perdeu para acompanhamento ou retirada do consentimento
Prazo: Até 27 meses
|
Até 27 meses
|
|
|
Overall survival (OS)
Prazo: Up to 27 months
|
OS defined as the time from first treatment administration until death from any cause. |
Up to 27 months
|
|
Overall survival at 6 and 12 months (OS6 and OS12)
Prazo: At 6 months and 12 months
|
OS defined as being alive at 6 months or at 12 months from first treatment administration. |
At 6 months and 12 months
|
|
Progression-free survival (PFS)
Prazo: Up to 27 months
|
PFS defined as the time from first treatment administration until disease progression (PD) according to RECIST v1.1 or death from any cause, whichever occurs earlier. |
Up to 27 months
|
|
Progression-free survival at 6 months (PFS6)
Prazo: At 6 months
|
PFS defined as being alive and without progression at 6 months from first treatment administration. |
At 6 months
|
|
Duration of objective response (DOR)
Prazo: Up to 27 months
|
DOR defined as the time from first documented CR or PR (RECIST v1.1) until the earliest of PD or death among patients with OR. |
Up to 27 months
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Neoplasias por Tipo Histológico
- Neoplasias de Cabeça e Pescoço
- Neoplasias Glandulares e Epiteliais
- Carcinoma
- Carcinoma de Células Escamosas
- Carcinoma Espinocelular de Cabeça e Pescoço
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Cetuximabe
- Pembrolizumab
Outros números de identificação do estudo
- 1501-0002
- U1111-1312-0435 (Identificador de registro: WHO International Clinical Trials Registry Platform (ICTRP))
- 2024-517091-38-00 (Identificador de registro: CTIS (EU))
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Prazo de Compartilhamento de IPD
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
Critérios de acesso de compartilhamento IPD
For study documents -upon signing of a 'Document Sharing Agreement'.For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .